Document is current
Any future updates will be listed below
-
Authors
Liu, Zheng
Gu, Wei-jie
Wan, Fang-ning
Chen, Zhang-zhe
Kong, Yun-yi
Liu, Xiao-hang
Ye, Ding-wei
Dai, Bo
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82303097, 82373355)
Shanghai Municipal Health Commission (2022XD013)
Shanghai Anti-Cancer Association (SACA-AX202302)
Shanghai Oriental Talent Program Top Project (BJKJ2024007)
PARP Inhibitor Cancer Research Fund (Phase 4) of China Anti-Cancer Association
- License Information
-
More Information
Article History
Received: 2 December 2024
Accepted: 19 May 2025
First Online: 27 May 2025
Declarations
:
: This study protocol involving human participants was reviewed and approved by the Institutional Review Board of Fudan University Shanghai Cancer Centre (Approval No. 050432-4-2108). Written informed consent was obtained from all participants.
: Not applicable.
: The authors declare no competing interests.
: Not applicable.
